Related Experiment Video
Updated: Mar 24, 2026
Murine Kidney Transplant Technique
Published on: October 20, 2015
Post-bone marrow transplant thrombotic microangiopathy
F Obut1, V Kasinath1, R Abdi1
1Transplantation Research Center, Department of Medicine, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Abstract:
Thrombotic microangiopathy (TMA) is a systemic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia and organ failure. Post-bone marrow transplant TMA (post-BMT TMA) is a life-threatening condition that has been reported to afflict between 0.5 and 63.6% of BMT patients. The incidence of post-BMT TMA is affected by evolving therapies such as conditioning regimens. The etiology of post-BMT TMA is thought to be multifactorial, including the effects of immunosuppressive agents, viral infections, TBI and GvHD. A growing body of evidence highlights the importance of complement system activation and endothelial damage in post-BMT TMA. Although plasmapheresis has commonly been used, its therapeutic rationale for the majority of post-BMT TMA cases is unclear in the absence of circulatory inhibitors. It has become possible to target complement activation with eculizumab, a drug that blocks the terminal complement pathway. Early studies have highlighted the importance of anti-complement therapies in treating post-BMT TMA. Moreover, finding complement gene mutations may identify patients at risk, but whether such patients benefit from prophylactic anti-complement therapies before BMT remains to be studied. This review focuses on diagnostic criteria, pathophysiology, treatment and renal outcomes of post-BMT TMA.
Insights
Thrombotic microangiopathy after bone marrow transplant (post-BMT TMA) is a serious complication. Complement system activation is key, and anti-complement therapies show promise for treatment.
Area of Science:
- Hematology
- Transplantation Immunology
- Nephrology
Background:
- Thrombotic microangiopathy (TMA) is a systemic disease causing anemia, low platelets, and organ failure.
- Post-bone marrow transplant TMA (post-BMT TMA) is a severe complication affecting 0.5–63.6% of patients.
- Complement system activation and endothelial damage are increasingly recognized as central to post-BMT TMA pathogenesis.
Purpose of the Study:
- To review diagnostic criteria, pathophysiology, and treatment strategies for post-BMT TMA.
- To discuss the role of complement activation and emerging anti-complement therapies.
- To examine renal outcomes in patients with post-BMT TMA.
Main Methods:
- Literature review focusing on diagnostic criteria, pathophysiology, and treatment of post-BMT TMA.
- Analysis of the role of complement system activation and endothelial damage.
- Evaluation of therapeutic interventions, including plasmapheresis and eculizumab.
Main Results:
- Post-BMT TMA etiology is multifactorial, involving immunosuppression, infections, TBI, and GvHD.
- Complement activation is a critical pathway in post-BMT TMA.
- Eculizumab, targeting the terminal complement pathway, shows therapeutic potential.
Conclusions:
- Anti-complement therapies are crucial for managing post-BMT TMA.
- Identifying complement gene mutations may aid in risk stratification.
- Further research is needed on prophylactic anti-complement therapies before BMT.
More Related Videos
10:31Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model
Published on: August 13, 2017
09:23Author Spotlight: Enhancing Transplantation Research Through MicroCT Angiography in Murine Models
Published on: September 22, 2023
Related Concept Videos
01:23Peripheral Artery Disease V: Postoperative Nursing Management
01:29Venous Thrombosis III: Interprofessional Care
01:16Kidney Transplant III: Nursing Management
01:30Venous Thrombosis I: Introduction